Utah Medical’s 483
This article was originally published in The Gray Sheet
Executive Summary
Response to FDA quality system inspection observations (form FDA-483) addresses an alleged lack of injection molding and extrusion operation validation, the firm says. The Salt Lake City firm, which has pending lawsuits against FDA seeking access to export certificates that have been denied due to alleged QS/GMP non-compliance dating to 2001, asserts it "has been and is in compliance with a reasonable interpretation" of FDA quality system regulations (1"The Gray Sheet" March 1, 2004, p. 14). The Feb. 2 through March 3 inspection report does not cite a lack of sterilization validation or failure to follow MDR report procedures, as was alleged after a 2003 inspection, the firm claims. "There were no current observations to suggest or support concern" about device safety or effectiveness, Utah says...
You may also be interested in...
Utah Medical Sues FDA For Export Certificates Denied Over GMP Findings
Utah Medical cites FDA's refusal to engage in "meaningful" dialogue about alleged good manufacturing practice deficiencies since 2001 as the origin of a dispute that has yielded two lawsuits against the agency
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.